<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="105761">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01741662</url>
  </required_header>
  <id_info>
    <org_study_id>2012-A01129-34</org_study_id>
    <secondary_id>2012-29</secondary_id>
    <nct_id>NCT01741662</nct_id>
  </id_info>
  <brief_title>Prevalence of Psychocognitive Impairments in Adolescents Surviving Childhood Leukemia : LEA-PsyCog</brief_title>
  <acronym>LEA-PsyCog</acronym>
  <official_title>Prevalence of Psychocognitive Impairments in Adolescents Surviving Childhood Leukemia : LEA-PsyCog</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique Hopitaux De Marseille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique Hopitaux De Marseille</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of the LEA-PsyCog project is to assess the prevalence of psychiatric disorders
      and psychocognitive impairments in adolescents surviving childhood leukemia .

      The second objective is to explore the complex relationships between psycocognitive
      development and soiciodemodemographics data, main characteristics of leukemia, treatments,
      side-effects, quality of life and characteristics of proxyies environment.

      3. Materials and Methods The LEA study is based on the constitution of a multi-centric
      prospective cohort in 11 university hospitals: Bordeaux, Clermont-Ferrand, Grenoble, Lyon,
      Paris (Trousseau, Robert Debré, St Louis), Marseille, Montpellier, Nancy, Nice, Rennes. Are
      inclued in LEA all the children diagnosed and treated for acute leukemia since January 1980
      (incident and prevalent cases), surviving  at month 24 for the AML and ALL grafted in
      complete remission and at month 48 for the ALL not grafted in first complete remission.

      The LEA Psy-Cog study rests on a sample of the LEA cohort. Are included the patients
      12-17-years-old from the PACA-Corse sub-cohort (administrative district of 4 million of
      people which corresponds to the Marseille and Nice centers). Patients from this two centers
      are the patients with the more important length of survey, allowing us to produce a not
      biaised estimation of prevalence rate. Finally, the choice of this subsample is supported by
      the proximity of the Mediterranean Center for Adolescent in Marseilles, specifically
      dedicated to the psychological follow-up of children suffering from cancer.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Diagnosis psychopathological</measure>
    <time_frame>36 months</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">170</enrollment>
  <condition>Adolescents Surviving Childhood Leukemia LEA</condition>
  <arm_group>
    <arm_group_label>group psychopathological</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>neuropsychological evaluation</intervention_name>
    <arm_group_label>group psychopathological</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  - Age 18-year-old subordinate at the time of the diagnosis;

          -  Diagnosis of acute(sharp) leukaemia;

          -  Diagnosis from January, 1980;

          -  Treatment(Processing) of the acute(sharp) leukaemia introduced in one of the
             inquiring centers (services(departments) specialized hematology and Clermont
             Ferrand's pediatric oncology, Grenoble, Lyon, Marseille, Nancy, Nancy, Nice, Paris -
             Robert Debré/Saint Debré/Saint Louis/Trousseau Louis/Trousseau;

          -  Living in France;

          -  Possessing a national insurance scheme

          -  24-month-old Survivor of recoil(drop) with regard to(compared with) the diagnosis for
             the Leukaemia Aiguës Myéloblastiques (LAM) and Leukaemia Aiguës Lymphoblastiques (
             LAL) transplanted in 1st complete forgiveness; or in 48 months of recoil(drop) with
             regard to(compared with) the diagnosis for the LAL not transplanted in first complete
             forgiveness;

        Exclusion Criteria:

          -  Failure to respect the criteria of inclusion beforehand quoted,

          -  Initial Treatment(Processing) realized except 2 participating centers (Marseille,
             Nice), even in case of moving in in the geographical zones covered by these centers
             during the phase of treatment(processing) or in the course of follow-up
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>BERNARD BELAIGUES</last_name>
    <role>Study Director</role>
    <affiliation>Assistance Publique Hopitaux De Marseille</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>david da fonseca</last_name>
    <email>david.dafonseca@ap-hm.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Assistance Publique Hopitaux de Marseille</name>
      <address>
        <city>Marseille</city>
        <zip>13354</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>david dafonseca</last_name>
      <email>david.dafonseca@ap-hm.fr</email>
    </contact>
    <investigator>
      <last_name>david dafonseca</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 17, 2013</lastchanged_date>
  <firstreceived_date>December 3, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Leukemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
